Home LiteratureArticle Details
PMID: 17562803 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?

Antimicrobial agents and chemotherapy ·Vol. 51 ·No. 8 ·2007-08-00 ·Pages 2883-7

Jump RL, Pultz MJ, Donskey CJ

Abstract

Proton pump inhibitors (PPIs) have been identified as a risk factor for Clostridium difficile-associated diarrhea (CDAD), though the mechanism is unclear because gastric acid does not kill C. difficile spores. We hypothesized that the vegetative form of C. difficile, which is killed by acid, could contribute to disease pathogenesis if it survives in room air and in gastric contents with elevated pH. We compared the numbers of C. difficile spores and vegetative cells in stools of patients prior to and during the treatment of CDAD. We assessed the survival of vegetative cells on moist or dry surfaces in room air versus anaerobic conditions and in human gastric contents, in pH-adjusted gastric contents, and in gastric contents from individuals receiving PPI therapy. Stool samples obtained from patients prior to the initiation of antibiotic treatment for C. difficile contained approximately 10-fold more vegetative cells than spores. On dry surfaces, vegetative C. difficile cells died rapidly, whereas they remained viable for up to 6 h on moist surfaces in room air. Vegetative C. difficile cells had only marginal survival in gastric contents at low pH; adjustment to a pH of >5 resulted in survival similar to that in the phosphate-buffered saline control. The survival of vegetative C. difficile in gastric contents obtained from patients receiving PPIs was also increased at a pH of >5. The ability of the vegetative form of C. difficile to survive on moist surfaces and in gastric contents with an elevated pH suggests a potential mechanism by which PPI therapy could increase the risk of acquiring C. difficile.

MeSH Terms
Aerobiosis Anaerobiosis Anti-Bacterial Agents/therapeutic use Anti-Ulcer Agents/therapeutic use Clostridioides difficile/growth & development,isolation & purification,physiology Colony Count, Microbial Diarrhea/microbiology Enterocolitis, Pseudomembranous/microbiology Feces/microbiology Gastrointestinal Contents/microbiology Humans Hydrogen-Ion Concentration Proton Pump Inhibitors Spores, Bacterial/physiology Water
Chemicals
Anti-Bacterial Agents Anti-Ulcer Agents Proton Pump Inhibitors Water
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Jump Robin L P
Louis Stokes Cleveland Veterans Affairs Medical Center, Infectious Diseases Section, Cleveland, OH 44106, USA.
Pultz Michael J
Donskey Curtis J
References (31)
31 references, click to expand
  1. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.
    N Engl J Med. 1999 Nov 25;341(22):1645-51 PMID: 10572152
  2. In vitro killing of nosocomial pathogens by acid and acidified nitrite.
    Antimicrob Agents Chemother. 2006 Nov;50(11):3901-4 PMID: 17065628
  3. Gastric acid suppression does not promote clostridial diarrhoea in the elderly.
    QJM. 2000 Mar;93(3):175-81 PMID: 10751237
  4. Survival of Clostridium difficile and its toxins in equine feces: implications for diagnostic test selection and interpretation.
    J Vet Diagn Invest. 2000 Jul;12(4):332-6 PMID: 10907862
  5. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.
    Clin Infect Dis. 2002 Feb 1;34(3):346-53 PMID: 11774082
  6. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea.
    Infect Control Hosp Epidemiol. 2002 Nov;23(11):653-9 PMID: 12452292
  7. The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces.
    J Clin Pathol. 2003 Feb;56(2):126-8 PMID: 12560391
  8. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea.
    J Hosp Infect. 2003 Jul;54(3):243-5 PMID: 12855243
  9. Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters.
    J Infect Dis. 2003 Dec 15;188(12):1922-7 PMID: 14673773
  10. Selective and differential medium for isolation of Clostridium difficile.
    J Clin Microbiol. 1979 Feb;9(2):214-9 PMID: 429542
  11. Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin.
    J Clin Microbiol. 1979 Dec;10(6):880-4 PMID: 521486
  12. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis.
    J Infect Dis. 1981 Jan;143(1):42-50 PMID: 7217711
  13. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection.
    Gastroenterology. 1982 Aug;83(2):465-9 PMID: 7084623
  14. Comparison of methods for recovery of Clostridium difficile from an environmental surface.
    J Clin Microbiol. 1983 Aug;18(2):348-52 PMID: 6619285
  15. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination.
    J Clin Microbiol. 1983 Oct;18(4):1017-9 PMID: 6630458
  16. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole.
    Br Med J (Clin Res Ed). 1984 Sep 22;289(6447):717-9 PMID: 6434053
  17. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster.
    J Infect Dis. 1985 Feb;151(2):355-61 PMID: 3968453
  18. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds.
    Gut. 1994 Apr;35(4):455-60 PMID: 8174980
  19. Conventional dose of omeprazole alters gastric flora.
    Dig Dis Sci. 1995 Sep;40(9):2070-3 PMID: 7555466
  20. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study.
    Gut. 1996 Jul;39(1):54-9 PMID: 8881809
  21. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity.
    Gut. 1999 May;44(5):598-602 PMID: 10205192
  22. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients.
    J Am Med Dir Assoc. 2005 Mar-Apr;6(2):105-8 PMID: 15871884
  23. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.
    Clin Infect Dis. 2005 Nov 1;41(9):1254-60 PMID: 16206099
  24. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
    N Engl J Med. 2005 Dec 8;353(23):2442-9 PMID: 16322602
  25. An epidemic, toxin gene-variant strain of Clostridium difficile.
    N Engl J Med. 2005 Dec 8;353(23):2433-41 PMID: 16322603
  26. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.
    JAMA. 2005 Dec 21;294(23):2989-95 PMID: 16414946
  27. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.
    Emerg Infect Dis. 2006 Mar;12(3):409-15 PMID: 16704777
  28. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea.
    Aliment Pharmacol Ther. 2006 Aug 15;24(4):613-9 PMID: 16907893
  29. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.
    CMAJ. 2006 Sep 26;175(7):745-8 PMID: 17001054
  30. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study.
    Clin Infect Dis. 2006 Nov 15;43(10):1272-6 PMID: 17051491
  31. Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery of Clostridium difficile.
    J Hosp Infect. 2000 Jan;44(1):65-9 PMID: 10633056
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
2007-08-00
Epub
2007-00-11
Pages
2883-7
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC1932506
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]